Role of TIEG1 in Foxp3+Treg development and tumor progression

TIEG1 在 Foxp3 Treg 发育和肿瘤进展中的作用

基本信息

  • 批准号:
    7943954
  • 负责人:
  • 金额:
    $ 49.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-30 至 2012-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Translational Science: Cancer as a systemic disease (15-CA-115): Although tumor vaccines can induce CD4 helper and CD8 cytotoxic response against tumor antigens, they have been largely ineffective in causing tumor regression in the clinic. This is because the tumor cells acquire many mechanisms to evade the immune surveillance program of the host. Foxp3+CD4+CD25+Treg-mediated immune suppression has emerged as one of the crucial tumor immune evasion mechanisms and main obstacle of successful tumor immunotherapy. Most malignant cells including prostate cancer cells secret large amounts of TGF-¿ and has been shown to convert the effector T cells into tumor antigen specific Tregs by inducing Foxp3 expression. Such tumor induced Tregs not only suppress the priming and effector function of anti-tumor effector cells but also form a broad network of self-amplifying immunosuppressive network. Therefore, overcoming tumor induced expansion and de novo generation of Tregs is critically important for the design of effective immunotherapeutic strategies for successful cancer treatment. We have demonstrated a critical role of TGF-¿ inducible early gene-1 (TIEG1) in the transcriptional regulation of Foxp3 in CD4T cells treated with TGF-¿. E3 ligase Itch-mediated monoubiquitination is essential for nuclear translocation, and transcriptional activation of TIEG1. However, in transient overexpression systems Itch targets TIEG1 for both mono and polyubiquitination. Our preliminary studies suggest that IL-6 which inhibits TGF-¿ induced Foxp3 expression induces proteasomal degradation of TIEG1 possibly through polyubiquitination. Tyk2-mediated phosphorylation of TIEG1 seems to act as a recognition signal for polyubiquitination of TIEG1. Therefore, we hypothesize that Itch targets TIEG1 differentially for mono and polyubiquitination when the CD4T cells are stimulated with TGF-¿ or IL-6 and regulates its activation and degradation. Despite the growing body of data on the role of Foxp3 in Treg development and function, how Foxp3 transcription is regulated is not clear. We have identified consensus NFAT and TIEG1 binding sites adjacent to each other on Foxp3 promoter. Since, most transcription factors work cooperatively with other factors binding in close proximity we hypothesize that NFAT and TIEG1 interact on Foxp3 promoter and regulate chromatin remodeling and Foxp3 expression. A clear understanding of molecular combinations and cross-talks that imprint Foxp3 transcription in CD4T cells will aid in designing strategies to disrupt the inhibitory network of Tregs in tumor microenvironment. Using prostate cancer TRAMP-C2 cells which secrete large amount of TGF-¿, we will analyze the effect of TIEG1 deficiency on Treg development and tumor progression. Since TIEG1 does not effect nTreg development in the thymus, targeting TIEG1 is an appealing strategy to block the de novo induction of Tregs. Such a strategy is expected to eliminate most potent tumor specific Tregs that inhibit anti-tumor immune response without the risk of triggering autoimmunity. PUBLIC HEALTH RELEVANCE: The application is in response to the Recovery Act Challenge Grant; Research Area: Translational Science Topic; (15-CA-115), Cancer as a systemic disease. This innovative application proposes to study the role of TGF-¿ inducible early gene-1(TIEG1) in the induction of Foxp3+Tregs by TGF-¿ secreted from tumor cells. The results obtained from these studies are expected gain significant new insights to maximize current immunotherapeutic approaches. In addition it complies with the spirit of the Challenge Grant as it will necessitate the hiring of new employees, especially in Detroit, Michigan which suffers from the highest unemployment rate in the country.
描述(由申请人提供):转化科学:癌症作为一种全身性疾病(15-CA-115):尽管肿瘤疫苗可以诱导针对肿瘤抗原的CD4辅助细胞和CD8细胞毒性反应,但在临床上,它们在引起肿瘤消退方面基本上无效。这是因为肿瘤细胞获得了许多机制来逃避宿主的免疫监视程序。Foxp3+CD4+CD25+ treg介导的免疫抑制已成为肿瘤重要的免疫逃避机制之一,也是肿瘤免疫治疗成功的主要障碍。包括前列腺癌细胞在内的大多数恶性细胞分泌大量TGF-¿,并通过诱导Foxp3表达将效应T细胞转化为肿瘤抗原特异性Tregs。这种肿瘤诱导的Tregs不仅抑制了抗肿瘤效应细胞的启动和效应功能,而且形成了一个广泛的自扩增免疫抑制网络。因此,克服肿瘤诱导的扩增和Tregs的新生对于设计有效的免疫治疗策略以成功治疗癌症至关重要。我们已经证明TGF-诱导的早期基因1 (TIEG1)在TGF-处理的CD4T细胞中对Foxp3的转录调节中起关键作用。E3连接酶瘙痒介导的单泛素化对核易位和TIEG1的转录激活至关重要。然而,在瞬时过表达系统中,Itch靶向TIEG1进行单泛素化和多泛素化。我们的初步研究表明抑制TGF-¿诱导的Foxp3表达的IL-6可能通过多泛素化作用诱导TIEG1的蛋白酶体降解。tyk2介导的TIEG1磷酸化似乎是TIEG1多泛素化的识别信号。因此,我们假设当CD4T细胞受到TGF-¿或IL-6刺激时,Itch对TIEG1的单泛素化和多泛素化作用存在差异,并调节其激活和降解。尽管关于Foxp3在Treg发育和功能中的作用的数据越来越多,但Foxp3的转录是如何被调节的尚不清楚。我们已经确定了Foxp3启动子上一致的NFAT和TIEG1结合位点相邻。由于大多数转录因子与其他紧密结合的因子协同工作,我们假设NFAT和TIEG1在Foxp3启动子上相互作用,调节染色质重塑和Foxp3表达。清楚地了解CD4T细胞中印记Foxp3转录的分子组合和交叉对话将有助于设计策略来破坏肿瘤微环境中Tregs的抑制网络。我们将利用分泌大量TGF-¿的前列腺癌trump - c2细胞,分析TIEG1缺乏对Treg发生和肿瘤进展的影响。由于TIEG1不影响胸腺中nTreg的发育,因此靶向TIEG1是阻断treg从头诱导的一种有吸引力的策略。这种策略有望消除大多数抑制抗肿瘤免疫反应的肿瘤特异性treg,而不会引发自身免疫的风险。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation.
  • DOI:
    10.1038/ni.2157
  • 发表时间:
    2011-11-06
  • 期刊:
  • 影响因子:
    30.5
  • 作者:
    Ahmed, Neesar;Zeng, Minghui;Sinha, Indrajit;Polin, Lisa;Wei, Wei-Zen;Rathinam, Chozhavendan;Flavell, Richard;Massoumi, Ramin;Venuprasad, K.
  • 通讯作者:
    Venuprasad, K.
Cbl-b and itch: key regulators of peripheral T-cell tolerance.
  • DOI:
    10.1158/0008-5472.can-09-4076
  • 发表时间:
    2010-04-15
  • 期刊:
  • 影响因子:
    11.2
  • 作者:
    Venuprasad K
  • 通讯作者:
    Venuprasad K
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Venuprasad K Poojary其他文献

Venuprasad K Poojary的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Venuprasad K Poojary', 18)}}的其他基金

Znf740 in the regulation of CD8+T cell exhaustion
Znf740 调节 CD8 T 细胞耗竭
  • 批准号:
    10715852
  • 财政年份:
    2023
  • 资助金额:
    $ 49.97万
  • 项目类别:
Regulation of RORγt in Th17-mediated inflammation
RORγt 在 Th17 介导的炎症中的调节
  • 批准号:
    10509373
  • 财政年份:
    2022
  • 资助金额:
    $ 49.97万
  • 项目类别:
Regulation of CD8+T cells by Zbtb42
Zbtb42 对 CD8 T 细胞的调节
  • 批准号:
    10661809
  • 财政年份:
    2022
  • 资助金额:
    $ 49.97万
  • 项目类别:
Regulation of RORγt in Th17-mediated inflammation
RORγt 在 Th17 介导的炎症中的调节
  • 批准号:
    10646293
  • 财政年份:
    2022
  • 资助金额:
    $ 49.97万
  • 项目类别:
Regulation of Zbtb44-Eomes complex in CD8+T cells and anti-tumor immunity
CD8 T 细胞中 Zbtb44-Eomes 复合物的调节和抗肿瘤免疫
  • 批准号:
    10377321
  • 财政年份:
    2021
  • 资助金额:
    $ 49.97万
  • 项目类别:
Regulation of Zbtb44-Eomes complex in CD8+T cells and anti-tumor immunity
CD8 T 细胞中 Zbtb44-Eomes 复合物的调节和抗肿瘤免疫
  • 批准号:
    10574602
  • 财政年份:
    2021
  • 资助金额:
    $ 49.97万
  • 项目类别:
Regulation of ROR-gt in colonic inflammation
ROR-gt 在结肠炎症中的调节
  • 批准号:
    9886237
  • 财政年份:
    2018
  • 资助金额:
    $ 49.97万
  • 项目类别:
Regulation of ROR-gt in colonic inflammation
ROR-gt 在结肠炎症中的调节
  • 批准号:
    10113592
  • 财政年份:
    2018
  • 资助金额:
    $ 49.97万
  • 项目类别:
Role of TIEG1 in Foxp3+Treg development and tumor progression
TIEG1 在 Foxp3 Treg 发育和肿瘤进展中的作用
  • 批准号:
    7830845
  • 财政年份:
    2009
  • 资助金额:
    $ 49.97万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.97万
  • 项目类别:
    Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 49.97万
  • 项目类别:
    Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 49.97万
  • 项目类别:
    Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 49.97万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 49.97万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 49.97万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 49.97万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 49.97万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 49.97万
  • 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 49.97万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了